Petera P, Tausch G, Bröll H, Eberl R
Int J Clin Pharmacol Biopharm. 1977 Dec;15(12):581-4.
Teorema and indometacin were administered to patients with degenerative and inflammatory joint diseases and degenerative vertebral column diseases for a period of 21 days. 24 patients were included in the 3 groups distinguished by diagnostic criteria. The daily Teorema dose was 420 mg in 21 cases and 210 mg in 3 cases; that of indometacin was 150 mg in 22 cases and 75 mg in 2 cases. Both drugs were given orally as capsules (25 mg indometacin/capsule and 70 mg Teorema/capsule). Both compounds produced a highly significant improvement of symptoms. Laboratory tests at regular intervals failed to reveal any substantial deviations from normal in both treatment groups. In conclusion, the results of the double blind trial suggest that Teorema, a new anti-inflammatory substance, when administered at a dose of approximately 420 mg/day, produces a beneficial effect in many rheumatoid conditions, while causing remarkably few side effects.
将Teorema和吲哚美辛给予患有退行性和炎性关节疾病以及退行性脊柱疾病的患者，为期21天。根据诊断标准将患者分为3组，共纳入24例患者。21例患者的Teorema每日剂量为420 mg，3例为210 mg；吲哚美辛22例患者的剂量为150 mg，2例为75 mg。两种药物均以胶囊形式口服（吲哚美辛25 mg/胶囊，Teorema 70 mg/胶囊）。两种化合物均使症状得到了高度显著的改善。定期进行的实验室检查未发现两个治疗组有任何明显偏离正常的情况。总之，双盲试验结果表明，新型抗炎物质Teorema以约420 mg/天的剂量给药时，在许多类风湿性疾病中产生有益效果，同时副作用极少。
